The neuropathological hallmarks of Alzheimer’s disease (AD) are extracellular plaques built up by the accumulation of the amyloid-β protein precursor (AβPP)-derived peptide β (Aβ), and intracellular tangles of hyperphosphorylated tau protein. Sirtuin 2 (SIRT2) is a member of the sirtuin family, featuring conserved enzymes with deacetylase activity and involved in several cell molecular pathways. We investigated the importance of SIRT2 inhibition in AD. We inhibited SIRT2 by small molecules (AGK-2, AK-7) and examined AβPP metabolism in H4-SW neuroglioma cells overexpressing AβPP and two AD transgenic mouse models (3xTg-AD and APP23). The in vitro studies suggested that the inhibition of SIRT2 reduced Aβ production; in vivo data showed an improvement of cognitive performance in the novel object recognition test, and an effect on AβPP proteolytic processing leading to a reduction of soluble β-AβPP and an increase of soluble α-AβPP protein. In 3xTg-AD mice, we noticed that total tau protein level rose. Overall, our pre-clinical data support a role for SIRT2 inhibition in the improvement of cognitive performance and the modulation of molecular mechanisms relevant for AD, thus deserving attention as possible therapeutic strategy.
BarkerWW, LuisCA, KashubaA, LuisM, HarwoodDG, LoewensteinD, WatersC, JimisonP, ShepherdE, SevushS, Graff-RadfordN, NewlandD, ToddM, MillerB, GoldM, HeilmanK, DotyL, GoodmanI, RobinsonB, PearlG, DicksonD, DuaraR (2002) Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord16, 203–212.
2.
MedaL, BaronP, ScarlatoG (2001) Glial activation in Alzheimer’s disease: The role of Abeta and its associated proteins. Neurobiol Aging22, 885–893.
3.
CraftS (2006) Insulin resistance syndrome and Alzheimer disease: Pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord20, 298–301.
4.
HaassC (2004) Take five–BACE and the gamma-secretase quartet conduct Alzheimer’s amyloid beta-peptide generation. EMBO J23, 483–488.
5.
SisodiaSS, KooEH, BeyreutherK, UnterbeckA, PriceDL (1990) Evidence that beta-amyloid protein in Alzheimer’s disease is not derived by normal processing. Science248, 492–495.
6.
EschFS, KeimPS, BeattieEC, BlacherRW, CulwellAR, OltersdorfT, McClureD, WardPJ (1990) Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science248, 1122–1124.
7.
CrowtherRA, OlesenOF, SmithMJ, JakesR, GoedertM (1994) Assembly of Alzheimer-like filaments from full-length tau protein. FEBS Lett337, 135–138.
8.
GoedertM (1993) Tau protein and the neurofibrillary pathology of Alzheimer’s disease. Trends Neurosci16, 460–465.
9.
GoedertM, CrowtherRA (1989) Amyloid plaques, neurofibrillary tangles and their relevance for the study of Alzheimer’s disease. Neurobiol Aging10, 405–406.
10.
GoedertM, SisodiaSS, PriceDL (1991) Neurofibrillary tangles and beta-amyloid deposits in Alzheimer’s disease. Curr Opin Neurobiol1, 441–447.
11.
PolitoL, KehoePG, ForloniG, AlbaniD (2010) The molecular genetics of sirtuins: Association with human longevity and age-related diseases. Int J Mol Epidemiol Genet1, 214–225.
12.
DonmezG (2012) The effects of SIRT1 on Alzheimer’s disease models. Int J Alzheimers Dis2012, 509529.
13.
ChenX, WalesP, QuintiL, ZuoF, MoniotS, HerissonF, RaufNA, WangH, SilvermanRB, AyataC, MaxwellMM, SteegbornC, SchwarzschildMA, OuteiroTF, KazantsevAG (2015) The sirtuin-2 inhibitor AK7 is neuroprotective in models of Parkinson’s disease but not amyotrophic lateral sclerosis and cerebral ischemia. PLoS One10, e0116919.
OddoS, CaccamoA, ShepherdJD, MurphyMP, GoldeTE, KayedR, MetherateR, MattsonMP, AkbariY, LaFerlaFM (2003) Triple-transgenic model of Alzheimer’s disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron39, 409–421.
20.
ColomboA, WangH, KuhnPH, PageR, KremmerE, DempseyPJ, CrawfordHC, LichtenthalerSF (2013) Constitutive α- and β-secretase cleavages of the amyloid precursor protein are partially coupled in neurons, but not in frequently used cell lines. Neurobiol Dis49, 137–147.
21.
ImbimboBP, Del GiudiceE, CenacchiV, VoltaR, VillettiG, FacchinettiF, RiccardiB, PucciniP, MorettoN, GrassiF, OttonelloS, LeonA (2007) In vitro and in vivoprofiling of CHF5022 and CHF5074. Two β-amyloid1-42 lowering agents. Pharmacol Res55, 318–328.
22.
WisseLEM, ReijmerYD, ter TelgteA, KuijfHJ, LeemansA, LuijtenPR, KoekHL, GeerlingsMI, BiesselsGJ (2015) Hippocampal disconnection in early Alzheimer’s disease: A 7 tesla MRI study. J Alzheimers Dis45, 1247–1256.
23.
MoodleyKK, ChanD (2014) The hippocampus in neurodegenerative disease. Front Neurol Neurosci34, 95–108.
24.
KuhnP-H, WangH, DislichB, ColomboA, ZeitschelU, EllwartJW, KremmerE, RossnerS, LichtenthalerSF (2010) ADAM10 is the physiologically relevant, constitutivealpha-secretase of the amyloid precursor protein in primary neurons. EMBO J29, 3020–3032.
25.
MerckenM, VandermeerenM, LübkeU, SixJ, BoonsJ, VanmechelenE, Van de VoordeA, GheuensJ (1992) Affinity purification of human tau proteins and the construction of a sensitive sandwich enzyme-linked immunosorbent assay for human tau detection. J Neurochem58, 548–553.
26.
JanelsinsMC, MastrangeloMA, OddoS, LaFerlaFM, FederoffHJ, BowersWJ (2005) Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer’s disease mice. J Neuroinflammation2, 23.
27.
MastrangeloMA, BowersWJ (2008) Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer’s disease-related pathologies in male triple-transgenic mice. BMC Neurosci9, 81.
28.
TheendakaraV, PatentA, Peters LibeuCA, PhilpotB, FloresS, DescampsO, PoksayKS, ZhangQ, CailingG, HartM, JohnV, RaoRV, BredesenDE (2013) Neuroprotective Sirtuin ratio reversed by ApoE4. Proc Natl Acad Sci U S A110, 18303–18308.
29.
MinSW, ChoSH, ZhouY, SchroederS, HaroutunianV, SeeleyWW, HuangEJ, ShenY, MasliahE, MukherjeeC, MeyersD, ColePA, OttM, GanL (2010) Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron67, 953–966.
30.
PolitoL, KehoePG, DavinA, BenussiL, GhidoniR, BinettiG, QuadriP, LuccaU, TettamantiM, ClericiF, BagnoliS, GalimbertiD, NacmiasB, SorbiS, GuaitaA, ScarpiniE, MarianiC, ForloniG, AlbaniD (2013) The SIRT2 polymorphism rs10410544 and risk of Alzheimer’s disease in two Caucasian case-control cohorts. Alzheimer Dement9, 392–399.
31.
WeiW, XuX, LiH, ZhangY, HanD, WangY, YanW, WangX, ZhangJ, LiuN, YouY (2014) The SIRT2 polymorphism rs10410544 and risk of Alzheimer’s disease: A meta-analysis. Neuromolecular Med16, 448–456.
32.
Sturchler-PierratC, StaufenbielM (2000) Pathogenic mechanisms of Alzheimer’s disease analyzed in the APP23 transgenic mouse model. Ann N Y Acad Sci920, 134–139.
33.
SperlingR, MorminoE, JohnsonK (2014) The evolution of preclinical Alzheimer’s disease: Implications for prevention trials. Neuron84, 608–622.
GreenKN, SteffanJS, Martinez-CoriaH, SunX, SchreiberSS, ThompsonLM, LaFerlaFM (2008) Nicotinamide restores cognition in Alzheimer’s disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci28, 11500–11510.
36.
LiuD, PittaM, JiangH, LeeJH, ZhangG, ChenX, KawamotoEM, MattsonMP (2013) Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: Evidence for improved neuronal bioenergetics and autophagy procession. Neurobiol Aging34, 1564–1580.
37.
De StrooperB (2010) Proteases and proteolysis in Alzheimer disease: A multifactorial view on the disease process. Physiol Rev90, 465–494.
38.
OddoS, CaccamoA, TranL, LambertMP, GlabeCG, KleinWL, LaFerlaFM (2006) Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem281, 1599–1604.
39.
AlmkvistO, BasunH, WagnerSL, RoweBA, WahlundLO, LannfeltL (1997) Cerebrospinal fluid levels of α-secretase-cleaved soluble amyloid precursor protein mirror cognition in a Swedish family with Alzheimer disease and a gene mutation. Arch Neurol54, 641–644.
NhanHS, ChiangK, KooEH (2015) The multifaceted nature of amyloid precursor protein and its proteolytic fragments: Friends and foes. Acta Neuropathol129, 1–19.
43.
JohnsonGV, HartiganJA (1999) Tau protein in normal and Alzheimer’s disease brain: An update. J Alzheimers Dis1, 329–351.
44.
Cambray-DeakinMA, BurgoyneRD (1987) Acetylated and detyrosinated alpha-tubulins are co-localized in stable microtubules in rat meningeal fibroblasts. Cell Motil Cytoskeleton8, 284–291.
45.
HempenB, BrionJP (1996) Reduction of acetylated alpha-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer’s disease. J Neuropathol Exp Neurol55, 964–972.
46.
ScuderiC, SteccaC, BronzuoliMR, RotiliD, ValenteS, MaiA, SteardoL (2014) Sirtuin modulators control reactive gliosis in an in vitro model of Alzheimer’s disease. Front Pharmacol5, 89.
47.
PerezJL, CarreroI, GonzaloP, Arevalo-SerranoJ, Sanz-AnquelaJM, OrtegaJ, RodriguezM, Gonzalo-RuizA (2010) Soluble oligomeric forms of beta-amyloid (Abeta) peptide stimulate Abeta production via astrogliosis in the rat brain. Exp Neurol223, 410–421.
